Altoida, Inc.

Altoida is in Lausanne this week for LausanneXII, one of the most influential forums shaping the future of Alzheimer’s innovation, regulation and clinical deployment. If you’re at the event or just in town, connect with our Head of Medical Strategy and Operations M. Florencia Iulita and VP of Medical Affairs Emmanuel Streel. Let’s accelerate the shift to early, precise detection of cognitive decline—at scale. #LausanneXII #Alzheimers #PrecisionMedicine #NeurologyInnovation #Neurodegeneration

We often talk about the importance of diversity in clinical data. As Marc Jones explains on the Health Connective Podcast: if your AI models are built only for the “mediums,” you miss everyone else. That’s exactly why Altoida has spent the past 18 months advancing the science and clinical validation of our Digital NeuroMarker Platform. Earlier this year, we completed a large multi-site study with 800 participants.  The data showed that our platform measures the same core constructs as established neuropsychological scales but with the critical advantage of detecting subtle changes much earlier. Hear Marc’s full conversation on the Health Connective Podcast here: https://lnkd.in/e72NkPCv #BrainHealth #EarlyDetection #Alzheimers #DigitalDiagnostics #AI #MedTech

Big step forward from Roche- FDA clearance for their pTau181 Alzheimer’s blood test. Well done! The future of brain health will come from combining accurate blood biomarkers like this with digital cognitive diagnostics like Altoida, Inc.’s NeuroMarker platform. This integration will enable scalable detection and monitoring, turning early detection into action and accelerating access and outcomes across neurological care. 🚀

Our CEO Marc Jones joins biotech and digital health leaders at Demy-Colton’s BioFuture on the panel "Healthspan Horizons: Advancing Longevity Therapeutics.” This panel will explore how emerging technologies, from AI-driven diagnostics to next-generation therapeutics, are redefining what it means to age well. Marc will share Altoida’s perspective on how early, precise detection of cognitive decline is essential to driving clinical adoption and advancing true healthspan, positioning brain health as the foundation of longevity. Join us at BioFuture 2025 in New York City on Oct. 13-15 to be part of the conversation shaping the future of healthy aging. #BioFuture #DigitalBiomarkers #Healthspan #DigitalDiagnostics #BrainHealth #AI #NeuroscienceInnovation

Altoida is advancing the inevitable standard in digital brain health diagnostics. Today, we strengthen that mission by welcoming Dr. Mona G. Flores, MD, Dr. Bryan J. Hansen, Ph.D., and Mike Zuendel to our Clinical and Scientific Advisory Board.   Their expertise, spanning AI innovation, pharma strategy, and patient advocacy, comes at a pivotal moment as we advance our Digital NeuroMarker Platform pivotal FDA study and prepare for rapid clinical adoption. With an estimated 200 million undiagnosed MCI patients worldwide, new disease modifying drugs now approved, and clinicians seeking tools to meet the challenge, the opportunity has never been greater. Read the full press release here: https://lnkd.in/eJqBCkG5 #BrainHealth #AI #DigitalDiagnostics #Alzheimers #PatientAdvocacy #PharmaInnovation #DigitalBiomarkers

New research milestone for Altoida! We are proud to announce that pilot data using Altoida’s Digital NeuroMarker Platform in Parkinson’s Disease (PD) is being presented at #MDS2025 in Honolulu, Hawaii. This marks the first demonstration in PD patients of the feasibility of an AI- and AR-powered digital cognitive assessment to detect early signs of Mild Cognitive Impairment (MCI). These findings highlight the potential of digital biomarkers to transform how clinicians identify and monitor cognitive changes in PD, laying the foundation for larger studies and future clinical applications. Emmanuel Streel will be at both the GP2 meeting at The Michael J. Fox Foundation for Parkinson's Research and the Movement Disorders Society conference this week to present and meet with industry partners. Send us a message if you’d like to schedule a time to connect with the team in person. Read the full abstract here: https://lnkd.in/grGxBGyG. K Ray Chaudhuri Nicholas Griffin, PhD Silvia Fallone M. Florencia Iulita Emmanuel Streel #Parkinsons #DigitalBiomarkers #EarlyDetection #AI #NeuroTech #BrainHealth

Altoida is honored to participate in the International Congress of Parkinson’s Disease and Movement Disorders, where Emmanuel Streel will present new research on the use of our Digital NeuroMarker Platform in patients with Parkinson’s Disease. Our study data highlights how AI- and AR-powered digital cognitive assessments can support clinicians in detecting and monitoring cognitive changes, offering a new lens on brain health in Parkinson’s. We’re proud to contribute to the global conversation on advancing diagnostics for neurodegenerative diseases and look forward to engaging with researchers, clinicians and innovators at #MDSCongress. #MDS2025 #Parkinsons #MovementDisorders #DigitalBiomarkers #NeuroTech #AI #BrainHealth

On World Alzheimer's Day, we reflect on a powerful reality: 55 million people globally are affected by Alzheimer's disease today. Published data suggest as many as 200 million people globally may have undiagnosed mild cognitive impairment (MCI) a known risk state and often a precursor to Alzheimer’s and other neurodegenerative diseases. Yet for millions, the path to early detection remains out of reach. The latest Alzheimer's Association report reveals something remarkable: - 79% of Americans would want to know if they had Alzheimer's before symptoms interfere with daily life, and; - 80% would ask to be proactively tested rather than wait for their doctor to suggest it. Despite affecting hundreds of millions of people worldwide, MCI is frequently undiagnosed, and traditional cognitive assessments remain largely unchanged. The tools haven't evolved to match the urgency of the need. Altoida’s Digital NeuroMarker Platform was built for this moment. By capturing millions of data points across speech, language, movement, and spatial navigation through smart device-based tasks that reflect real-world activities, it is designed to reveal subtle cognitive changes invisible to traditional tests. The aim is to enable detection at the earliest stages when timely intervention can have the greatest impact. People are ready for earlier answers. Treatments are advancing. What is needed now are diagnostic platforms that connect patients’ expectations with clinical practice while being accessible at scale. On World Alzheimer’s Day, we reaffirm our mission to deliver solutions that make this possible. Read more in the Alzheimer’s Association 2025 Facts and Figures Report: https://lnkd.in/gdhWxmC #WorldAlzheimersDay #BrainHealth #EarlyDetection #DigitalHealth #AI #Alzheimers #MedTech

We’re excited to share that our CEO, Marc Jones, is featured on the Health Connective Podcast! Marc talks about how Altoida’s Digital NeuroMarker Platform aims to redefine the standard for brain health diagnostics by capturing real-world data to detect cognitive decline earlier than traditional tools, at a point when interventions can be most effective. The conversation explores why earlier detection matters, what it means for patients and families, and how platforms like Altoida are shaping the future of brain health in clinical practice and clinical trials. 🎧 Listen to the episode here: https://lnkd.in/e72NkPCv #BrainHealth #EarlyDetection #Alzheimers #DigitalDiagnostics #AI #MedTech

At #LSIEurope25 in London this week, our CEO Marc Jones shared the Altoida story and a core truth that resonated across the room: nearly 200 million people globally are living with undiagnosed Mild Cognitive Impairment (MCI).  The vast majority are likely eligible for disease-modifying interventions, yet they don’t find out early enough to benefit, if at all. What if a diagnostic platform like Altoida could reveal to someone they were on a path toward Alzheimer’s before symptoms appear, and opened the door to interventions early enough to preserve independence and alter the course of the disease? This is the vision driving Altoida: a tablet-based, multi-modal diagnostic tool powered by AR and AI to detect subtle cognitive changes earlier than traditional methods and enable timely intervention. Thank you to the LSI community for the opportunity to share our mission and to connect with leaders committed to advancing neurological care. #LSIEurope25 #DigitalDiagnostics #BrainHealth #AI #Alzheimer #EarlyDetection #MCI